Methylglyoxal chronic administration promotes diabetes-like cardiac ischaemia disease in Wistar normal rats

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 23, Issue 12, 2013, Pages 1223-1230

  Crisostomo J ^a   Matafome, P ^a,b   Santos Silva, D ^a   Rodrigues, L ^a   Sena, C M ^a   Pereira, P ^b   Seica R ^a  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Cardiac ischemia; Hyperglycemia; Methylglyoxal; Type 2 diabetes

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; CARBONYL DERIVATIVE; FATTY ACID; HEMOGLOBIN A1C; METHYLGLYOXAL; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; DOT HYBRIDIZATION; FLUORESCENCE ANALYSIS; HEART MUSCLE CELL; HEART MUSCLE ISCHEMIA; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; RAT; REGULATORY MECHANISM; WESTERN BLOTTING;

ANIMALIA; RATTUS; RODENTIA;

CARDIAC ISCHEMIA; HYPERGLYCEMIA; METHYLGLYOXAL; TYPE 2 DIABETES;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, TYPE 2; GLYCOSYLATION END PRODUCTS, ADVANCED; HEART; MALE; MYOCARDIAL ISCHEMIA; OXIDATIVE STRESS; PYRUVALDEHYDE; RATS; RATS, WISTAR;

EID: 84888838277     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2013.01.005     Document Type: Article

References (30)

1. Stolar M.W., Chilton R.J. Type 2 diabetes, cardiovascular risk, and the link to insulin resistance. Clin Ther 2003, 25:4-31.
2. Ferdinandy P., Schulz R., Baxter G.F. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007, 59:418-458.
3. Lee Y., Gustafsson A.B. Role of apoptosis in cardiovascular disease. Apoptosis 2009, 14:536-548.
4. Matsui T., Tao J., del Monte F., Lee K.H., Li L., Picard M., et al. Akt activations preserves cardiac function and prevents injury after transient cardiac ischemia invivo. Circulation 2001, 104:330-335.
5. Miao W., Luo Z., Kitsis R.N., Walsh K. Intracoronary, adenovirus-mediated Akt gene transfer in heart limits infarct size following ischemia-reperfusion injury invivo. J Mol Cell Cardiol 2000, 32:2397-2402.
6. Kalapos M.P. The tandem of free radicals and methylglyoxal. Chem Biol Interact 2008, 171:251-271.
7. Goldin A., Beckman J.A., Schmidt A.M., Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006, 114:597-605.
8. Hsuuw Y., Chang C., Chan W., Yu J. Curcumin prevents methylglyoxal-induced oxidative stress and apoptosis in mouse embryonic stem cell and blastocysts. J Cell Physiol 2005, 205:379-386.
9. Beisswenger P.J., Howell S.K., Nelson R.G., Mauer M., Szwergold B.S. Alpha-oxoaldehyde metabolism and diabetic complications. Biochem Soc Trans 2003, 31:1358-1363.
10. Lu J., Randell E., Han Y., Adeli K., Krahn J., Meng Q.H. Increased plasma methylglyoxal level, inflammation, and vascular endothelial dysfunction in diabetic nephropathy. Clin Biochem 2011, 44:307-311.
11. Berlanga J., Cibrian D., Guillén I., Freyre F., Alba J.S., Lopez-Saura P., et al. Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond) 2005, 109:83-95.
12. Riboulet-Chavey A., Pierron A., Durand I., Murdaca J., Giudicelli J., Van Obberghen E. Methylglyoxal impairs the insulin signalling pathways independently of the formation of intracellular reactive oxygen species. Diabetes 2006, 55:1289-1299.
13. McLellan A.C., Thornalley P.J., Benn J., Sonksen P.H. The glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci (Lond) 1994, 87:21-29.
14. Dhar A., Desai K., Kazachmov M., Yu P., Wu L. Methylglyoxal production in vascular smooth muscle cells from different metabolic precursors. Metabolism 2008, 57:1211-1220.
15. Guo Q., Mori T., Jiang Y., Hu C., Osaki Y., Yoneki Y., et al. Methylglyoxal contributes to the development of insulin resistance and salt sensitivity in Sprague-Dawley rats. J Hypertens 2009, 27(8):1664-1671.
16. Wang X.L., Lau W.B., Yuan Y.X., Wang Y.J., Yi W., Christopher T.A., et al. Methylglyoxal increases cardiomyocyte ischemia-reperfusion injury via glycative inhibition of thioredoxin activity. Am J Physiol Endocrinol Metab 2010, 229(2):E207-E214.
17. Dhar A., Dhar I., Jiang B., Desai K.M., Wu L. Chronic methylglyoxal infusion by minipump causes pancreatic β-cell dysfunction and induces type 2 diabetes in Sprague-Dawley rats. Diabetes 2011, 60:899-908.
18. Vander Jagt D.L. Methylglyoxal, diabetes mellitus and diabetic complications. Drug Metabol Drug Interact 2008, 23:93-124.
19. Sena C.M., Matafome P., Crisóstomo J., Rodrigues L., Fernandes R., Pereira P., et al. Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacol Res 2012, 65:497-506.
20. Matafome P., Santos-Silva D., Crisóstomo J., Rodrigues T., Rodrigues L., Sena C.M., et al. Methylglyoxal causes structural and functional alterations in adipose tissue independently of obesity. Arch Physiol Biochem 2012, 118:58-68.
21. Crisóstomo J., Rodrigues L., Matafome P., Amaral C., Nunes E., Louro T., et al. Beneficial effects of dietary restriction in type 2 diabetic rats: the role of adipokines on inflammation and insulin resistance. Br J Nutr 2010, 104:76-82.
22. Yakubovich N., Gerstein H.C. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 2011, 123:342-348.
23. Giacco F., Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010, 107:1058-1070.
24. Thornalley P.J., Battah S., Ahmed N., Karachalias N., Agalou S., Babaei-Jadidi R., et al. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry. Biochem J 2003, 375:581-592.
25. Bucciarelli L.G., Ananthakrishnan R., Hwang Y.C., Kaneko M., Song F., Sell D.R., et al. RAGE and modulation of ischemic injury in the diabetic myocardium. Diabetes 2008, 57:1941-1951.
26. Hudson B.I., Schmidt A.M. RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm Res 2004, 21:1079-1086.
27. El-Omar M.M., Yang Z., Philips A.O., Shah A.M. Cardiac dysfunction in Goto-Kakizaki rat. Basic Res Cardiol 2004, 99:133-141.
28. Moens A.L., Claeys M.J., Timmermans J.P., Vrints C.J. Myocardial ischuemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol 2005, 100:179-190.
29. Danial N.N., Korsmeyer S.J. Cell death: critical control points. Cell 2004, 116:205-219.
30. Hochhauser E., Kivity S., Offen D., Maulik N., Otani H., Barhum Y., et al. Bax ablation protect against myocardial ischemia-reperfusion injury in cardiac miocytes. Am J Physiol Heart Circ Physiol 2003, 284:H2351-H2359.